X-linked Intellectual Disability Gene Mutation Panel, NGS
An X-linked intellectual disability gene mutation panel detects mutations associated with intellectual disability where the pedigree is suggestive of an X-linked pattern of inheritance. Intellectual Disability (ID) is a childhood-onset neurodevelopmental disorder, more commonly seen in males, characterized by significant limitations in intellectual functioning, impairments in adaptive behavior and an intelligence quotient below 70. ID is diagnosed in ~1-3% of the total population, and X-linked gene mutations account for ~5-10% of ID cases in males. The X-linked syndromes associated with intellectual disability include Coffin-Lowry syndrome, Fragile X syndrome, MASA syndrome, MECP2 duplication syndrome (M2DS), Alpha-thalassemia mental retardation syndrome (ATRX) and Intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH).
Coffin–Lowry syndrome is an X-linked dominant disorder associated with severe mental problems, abnormalities of growth, cardiac abnormalities, kyphoscoliosis, as well as auditory and visual abnormalities. As they have two X chromosome, females are less affected than a males. The disorder may present in childhood or adolescence, and patients may experience brief ‘stimulus-induced drop episodes’ (SIDEs) which are characterized by sudden collapse when the patient is excited or startled by a loud noise clinical features also include distinctive facial features, soft hands with short, tapered fingers, short stature, microcephaly, kyphoscoliosis, and other skeletal abnormalities. This syndrome is caused by mutations in the RPS6KA3 gene that result in the production of little or no RPS6KA3 protein. This affects cell-signaling pathways that are required for learning, the formation of long-term memories, and the survival of nerve cells.
Fragile X syndrome is an X-linked dominant genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. About one-third of individuals with fragile X syndrome have features of autism spectrum disorder that affect communication and social interactions. As with Coffin-Lowry, males are more severely affected in this disorder than females. Clinical features include long, narrow face, large ears, a prominent jaw and forehead, unusually flexible fingers, flat feet, and in males, enlarged testicles (macroorchidism) after puberty. Fragile X is caused by expansion of the CGG triplet repeat in the FMR1 gene. Normally, there are from 5 to about 40 repeats in FMR1, however, patients with fragile X syndrome the CGG repeat is expanded more than 200 times. Hypermethylation of the expanded CGG repeats results in silencing of the FMR1 gene which prevents the production of FMRP. Loss or a shortage (deficiency) of this protein disrupts nervous system functions and leads to the signs and symptoms of fragile X syndrome.
MASA syndrome is a rare X-linked recessive neurological disorder on the L1 disorder spectrum belonging in the group of hereditary spastic paraplegias primarily affecting the lower limbs. MASA stands for Mental retardation, Aphasia, Spastic paraplegia and Adducted thumbs the cardinal features of the disorder. It is also known as CRASH syndrome and Gareis-Mason syndrome. MASA syndrome has been associated with variants in the L1CAM gene. Over 350 mutations have been described and include nonsense, missense and large insertions or deletions. Mutations in L1CAM gene either result in lack of a gene product or an abnormal protein that disrupts normal neuronal functions.
MECP2 duplication syndrome (M2DS) is a rare disease that is characterized by severe intellectual disability and impaired motor function. It is an X-linked disorder caused by duplication of the MECP2 or Methyl CpG binding protein 2 gene located on the X chromosome (Xq28) and overexpression of MeCP2 protein. Increased levels of MECP2 protein results in abnormal neural function and impaired immune system. Symptoms of M2DS include infantile hypotonia and failure to thrive, delayed psychomotor development, impaired speech, abnormal gait, epilepsy, spasticity, gastrointestinal motility problems, recurrent infections, and genitourinary abnormalities.
Alpha-thalassemia mental retardation syndrome (ATRX) also called alpha-thalassemia X-linked mental retardation, nondeletion type or ATR-X syndrome, is an X-linked recessive disorder caused by mutation in the ATRX gene. Males are moderately intellectually disabled and have physical characteristics that include coarse facial features, microcephaly, hypertelorism, depressed nasal bridge, tented upper lip and everted lower lip. Most affected individuals also have mild alpha thalassemia. Females carriers of this mutated gene typically have no clinical findings, unless they have skewed X chromosome inactivation (lyonization).
Intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH) is a rare X-linked dominant disorder of brain development, also known as mental retardation, X-linked, syndromic, Najm type (MRXSNA). Infants may demonstrate intellectual disability and pontocerebellar hypoplasia. Individuals with MICPCH may also have sleep disturbances and exhibit self-biting, hand flapping, or other abnormal repetitive behaviors, sensorineural hearing loss, eye problems such as strabismus, arched eyebrows, broad nose, hypotonia, spasticity, and dystonia. Clinically it is usually seen in females as most males with the disorder die before birth or not long after. MICPCH is caused by mutations in the CASK gene that affect the role of the CASK protein in brain development and function.
Panel Components
Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: ACSL4, CLIC2, GK, KLF8, NSDHL, PRPS1, TIMM8A, AFF2, CNKSR2, GPC3, L1CAM, OCRL, PTCHD1, TSPAN7, AP1S2, CUL4B, GRIA3, LAMP2, OFD1, RAB39B, UBE2A, ARHGEF9, DCX, HCCS, MAOA, OPHN1, RBM10, UPF3B, ARX, DKC1, HCFC1, MBTPS2, OTC, RPL10, ZDHHC9, ATP6AP2, DLG3, HPRT1, MECP2, PAK3, RPS6KA3, ZDHHC15, ATP7A, DMD, HSD17B10, MED12, PCDH19, SHROOM4, ZNF711, ATRX, FANCB, HUWE1, MID1, PDHA1, SLC9A6, BCOR, FGD1, IDS, NAA10, PGK1, SLC16A2, BRWD3, FLNA, IGBP1, NDP, PHF6, SMC1A, CASK, FMR1, IL1RAPL1, NDUFA1, PHF8, SMS, CCDC22, FRMPD4, IQSEC2, NHS, PLP1, SOX3, CDK16, FTSJ1, KDM5C, NLGN3, PORCN, SYN1, CDKL5, GDI1, KIAA2022, NLGN4X, PQBP1, SYP associated with X-linked intellectual disability (XLID).
- To confirm the clinical diagnosis of X-Linked Intellectual Disability (XLID)
- As an aid in diagnosis and management of Fragile X syndrome
- To identify the disease-causing mutations within a family to allow for carrier testing and prenatal diagnosis
- For pre-conception planning for potentially at-risk individuals
- At least one known pathogenic variant or mutation (deletion or duplication) associated with X-linked intellectual disability should be detected
- Expansion of CGG segment >200 in FMR1 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants
- Normal:5−44 Intermediate (Gray Zone): 45−54 Premutation: 55−200 Full mutation: >200
Negative for mutation (deletion or duplication) or pathogenic variant in the genes tested Normal Expansion of CGG triplet repeatsin FMR1 gene CGG triple repeats: 5−44
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Clin Genet. 2020;97: 677-687. [PMID: 31898314]
- Am J Med Genet A. 2018;176: 1375-1388. [PMID: 29696803]
- Eur J Med Genet. 2016;59: 347-53. [PMID: 27180140]
- Curr Psychiatry Rep. 2010;12: 127-34. [PMID: 20425298]
- Nat Genet. 2008;40: 1065-7. [PMID: 19165920]
- J Pediatr Orthop. 2007;27: 85-9. [PMID: 17195803]
- Orphanet J Rare Dis 2006;1:15. [PMID: 16722615]
- J Med Genet. 2002;39: 705-13. [PMID: 12362025]
- Am J Med Genet. 2000;92: 40-6. [PMID: 10797421]